Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

CTXR

Rank in Stocks #27618
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm... Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Share Price
$0.5324
Last synced: 2026-11-12
Market Cap
$13.93M
Change (1 day)
10.78%
Change (1 year)
-50.24%
Country

Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this

Trade Citius Pharmaceuticals, Inc. (CTXR)

Category

Healthcare
EPS for Citius Pharmaceuticals, Inc. (CTXR)
EPS as of June 2026 TTM: $-2.11
According to Citius Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-2.11. At the end of 2025 the company had an EPS of $-3.38, an increase over its 2024 EPS of $-5.97.
EPS history for Citius Pharmaceuticals, Inc. from 2011 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-2.11 -37.57%
2025 $-3.38 -43.38%
2024 $-5.97 7.18%
2023 $-5.57 -3.13%
2022 $-5.75 1.95%
2021 $-5.64 -49.64%
2020 $-11.20 1,354.55%
2019 $-0.77 -34.19%
2018 $-1.17 -38.10%
2017 $-1.89 -17.47%
2016 $-2.29 67.15%
2015 $-1.37 44.21%
2014 $-0.95 2,172.73%
2013 $-0.04 42.66%
2012 $-0.03 -16.52%
2011 $-0.04 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 -57.82%
US
$15.66 -842.18%
US
$-7.07 235.07%
US
$-5.29 150.71%
AU
$12.73 -703.42%
BE

Questions about Citius Pharmaceuticals, Inc.'s earnings per share (EPS)

What is Citius Pharmaceuticals, Inc.'s earnings per share (EPS)?

Citius Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-2.11, as of Jun 2026.

What was Citius Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?

In 2025, Citius Pharmaceuticals, Inc.'s earnings per share (EPS) was $-3.38, compared with $-5.97 in 2024.

How has Citius Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Citius Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2025 ($-3.38) and lowest in 2020 ($-11.20).

How does Citius Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?

Citius Pharmaceuticals, Inc.'s earnings per share (EPS) ($-2.11) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.